March 7, 2025 01:25 PM ESTUpdated 02:35 PM
Deals
Cell/Gene Tx

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Kyle LaHucik

Senior Reporter

Blue­bird bio went from a high-fly­ing $10 bil­lion com­pa­ny in 2018 dur­ing the hey­day of gene ther­a­py to be­ing sold for a measly $29 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Teenag­er dies af­ter re­ceiv­ing Sarep­ta ther­a­py; Im­muno­vant gets Phase 3 win, but shifts fo­cus; Al­ny­lam’s big mo­ment; ...

Liv­er can­cer drug com­bo gets sec­ond FDA re­jec­tion over man­u­fac­tur­ing is­sues

Trump think tank res­ur­rects in­ter­na­tion­al drug pric­ing mod­el to go af­ter 'glob­al free­load­ing'

Al­ny­lam hopes its broad AT­TR-CM la­bel can give Amvut­tra an edge in heart dis­ease

BAR­DA can­cels an­nu­al bio­med­ical event for in­dus­try, gov­ern­ment reps

The buildup to Chimerix's $935M ex­it to Jazz, with more than half a dozen par­ties in­trigued

A service from the Financial Times